Sarepta Therapeutics Stock News

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.

Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasd

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD

Sarepta Therapeutics is successfully developing treatments for a rare and devastating disease. Shopify's recent moves should make it even stronger in the fast-growing e-commerce industry.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi

Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some important challenges that could stunt its growth.

CRISPR Therapeutics is using a novel technique to develop innovative therapies. Sarepta Therapeutics is developing medicines targeting a difficult-to-treat disease.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Kl

Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to loss of $2.65 per share a year ago.

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impacted the stock but could expand with a successful co

There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.

Sarepta Therapeutics Inc. SRPT, -0.90% said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million and will use the proceeds for R&D. Sarepta was aw